Stroke remains a major cause of death in the US and around the world. Over the last decade, stem cell therapy has been introduced as an experimental treatment for stroke. Transplantation of stem cells or progenitors into the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endogenous stem or progenitor cells stand as the two major cell-based strategies. Potential sources of stem/progenitor cells for stroke include fetal neural stem cells, embryonic stem cells, neuroteratocarcinoma cells, umbilical cord blood-derived nonhematopoietic stem cells, and bone marrow-derived stem cells. The goal of this article is to provide an update on the preclinical use of bone marrow-derived stem cells with major emphasis on mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) because they are currently most widely applied in experimental stroke studies and are now being phased into early clinical trials. The phenotypic features of MSCs and MAPCs, as well as their application in stroke, are described.
INTRODUCTION
. Cell-based therapeutics appear to promote both brain plasticity and remodeling mechanisms, thereby providing novel approaches to treating stroke. Cell-Stroke is the third leading cause of death and the primary cause of disability in the US, which accounts for based strategies can be classified into two categories, namely transplantation of stem cells or progenitors into the majority of total healthcare costs. According to the American Stroke Association estimate, the prevalence of the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endog-stroke is 2.6%, with 700,000 people experiencing a new or recurrent attack. The estimated direct and indirect enous stem or progenitor cells. For transplantation of exogenous stem cells, there are various cell types that cost of stroke for 2006 is $57.9 billion (81) . Despite intensive research, few treatment options exist. Throm-serve as potential sources, such as neural stem cells (NSCs) (20) , NT2 neurons (NT2N) (5), umbilical cord bolytic therapy via recombinant tissue plasminogen-activator (rtPA) inhibitor is the only therapy so far proven blood-derived nonhematopoietic stem cells (6,61), embryonic stem cells (31, 79) , and bone marrow-derived to be effective, yet this therapy requires drug treatment within 3 h of onset of stroke. This highly restrictive time stem cells (89) . This article will focus on bone marrowderived stem cells, highlighting their advantages as a constraint has limited the use of rtPA to approximately 2% of stroke patients in the US (41). Even among pa-nonembryonic stem cell source, thereby circumventing ethical as well as logistical problems in obtaining these tients fortunate enough to receive thrombolytic therapy, only 40% show beneficial outcome through this proce-cells. To this end, the advent of adult bone marrowderived stem cells, such as mesenchymal stem cells dure (23, 58, 80) . Accordingly, novel therapeutic strategies need to be developed.
(MSCs) and multipotent adult progenitor cells (MAPCs) has advanced the field of cell transplantation. Brain plasticity and remodeling have been proposed as potential restorative mechanisms following stroke Bone marrow consists of multiple stem cell subpopu-lations. Based on differentiation potential at clonal level, (2) . Kobune's study reveals that MSCs exhibit a reduced mitogenic activity after about 5 PDs over the course of bone marrow-derived stem cells mainly fall into two broad categories: multipotent stem cells and pluripotent about 6 weeks and undergo crisis at 16 PDs (42) . Bruder and colleagues demonstrate that the growth rate of stem cells. Multipotent stem cells include hematopoietic and nonhematopoietic stem cells such as MSCs. MSCs
MSCs decreases with passaging, in that the PDs for hMSCs before degenerating are around 38, even though could differentiate into osteoblasts, chondroblasts, adipocytes, and skeletal muscle (65,67,68). There are re-the osteogenic differentiation potential is preserved (7). Cumulative population doubling level (CPDL) for ports demonstrating that MSCs could differentiate into neurons and hepatocytes besides the mesodermal cell hMSCs selected with serum-deprived medium is about 9 PDs at passage 10, while for hMSCs selected with lineages (51, 82) . However, these studies use MSCs that are not isolated at the single cell level, raising the possi-regular medium, CPDL is about 7 PDs at passage 8 (66) . Although evidence on the limitation of MSCs' differen-bility that the initial isolated groups of cells comprise more than one cell population. Pluripotent stem cells are tiation and proliferation potential exists, a report from Pittenger and colleagues indicates that MSCs maintain capable of differentiation into the three germ lineage cells. There are several subsets reported by different lab-telomerase activity in both early and late passage (65). The discrepancy here might be due to the fact that cell oratories that adopt this multilineage differentiation potential at the clonal level, such as MAPCs (40), marrow-phenotypes isolated from different laboratories are distinct. isolated adult multilineage inducible (MIAMI) cells (25) , human bone marrow-derived multipotent stem cells Gene manipulation strategy has been utilized to overcome MSCs' senescent problem. Hamada and colleagues (hBMSCs) (84) , and very small embryonic-like (VSEL) stem cells (46) . Table 1 summarizes milestones, while transfect MSCs with the human telomerase gene by retroviral infection to generate stable cell clones with high Figure 1 illustrates basic subsets of bone marrow-derived stem cells. efficiency and low cell mortality (30, 36, 47) . These cells, regarded as hTERT-MSCs, can survive in culture for We describe here the main characteristics of bone marrow-derived nonhematopoietic multipotent stem cells over 1 year and maintain their characteristic surface antigens as well as typical morphology. Cerebral infarction and pluripotent stem cells, as well as their application in stroke. We focus on MSCs and MAPCs because they volume is significantly reduced and functional outcome is improved in hTERT-MSCs-treated stroke animal are currently most widely applied in experimental stroke studies and are now being phased into early clinical model (36). trials (3) .
MSC Transplantation in Stroke MULTIPOTENT BONE MARROW-DERIVED
MSCs have been employed in experimental stroke NONHEMATOPOIETIC STEM CELLS-MSCs models and shown to improve the functional recovery of neurological deficits induced by cerebral ischemia Characteristics of MSCs (3, 14, 15, 19, (53) (54) (55) (56) 69, 77) . Clinical reports of MSC Mesenchymal stem cells (MSCs) are initially retransplantation in stroke patients reveal that MSCs sigported by Friedenstein and Owen (26) , referring to a nificantly improve the functional recovery of patients population of plastic-adherent fibroblastic cells isolated without adverse side effects (3) . The underlying mechaby Percoll density centrifugation. Human MSCs (hMSCs) nism remains unclear. The subsequent sections address express CD105 (SH2), SH3, Stro-1, and CD13, but lack some potential mechanisms that might mediate the therthe hematopoietic surface markers, CD34 and CD45.
apeutic effects of MSC implantation in stroke. MSCs have the potential to differentiate into mesodermal cell lineages such as adipocytes, chondroblasts, fi-Trophic Factor Secretion. Neuronal differentiation as the underlying mechanism for grafted MSCs to pro-broblasts, osteoblasts, and skeletal myoblasts both in vitro and in vivo (29, 32, 60, 63, 67) . hMSCs lack telome-duce therapeutic benefits remains controversial. Moreover, transplantation of MSCs, via intravenous, intracar-rase activity, with about 18 population doublings (PDs) (91) . A study conducted at the single cell level by Mura-otid, or even intracerebral delivery, leads to very low, or at best modest, graft survival rate (73) . A far more glia and colleagues demonstrates MSCs with capability of differentiation into osteogenic, chondrogenic, and ad-reasonable explanation for the graft-derived beneficial effects is that MSCs secrete neurotrophic factors that ipogenic phenotype up to 19 PDs, then lose their apparent proliferation potential at 22-23 PDs in about 80 days may induce the host ischemic brain to activate endogenous repair mechanisms. Chopp and colleagues show in culture (60) . Strikingly similar to this study, clonal hMSCs cultured in vitro by Banfi and coworkers are that MSCs produce hepatocyte growth factor (HGF) (18) , vascular endothelial growth factor (VEGF) (17) , also found to gradually lose the differentiation potential when reaching 22-23 PDs after about 80 days of culture nerve growth factor (NGF) (52), brain-derived neuro- OCA cells: osteogenic, chondrogenic and adipogenic cells; PDs: population doublings; CPDL: Cumulative population doubling level; PP: proliferation potential; MDP: multiple lineages differentiate potential; Not addressed: authors did not describe this topic in their study; Negative/positive: the activity of telomerase is negative or positive. trophic factor (BDNF) (18, 52) , basic fibroblast growth within the SVZ and the SGZ into the injured brain (12,52,53). The newly differentiated cells appear as pro-factor (bFGF, FGF-2) (12), and insulin growth factor-1 (IGF-1) (87). These neurotrophic cytokines have been genitor-like neurons and astrocytes. The process of neurogenesis is highly dependent upon the neurotrophic fac-implicated to play an important role in the process of neurogenesis and angiogenesis. For instance, the upreg-tors secreted by MSCs (12). Upregulation of BDNF levels is proven to be capable of recruiting neural pro-ulation of VEGF and the VEGF receptor 2 (VEGFR2) at the impaired site could increase the number of en-genitors from the endogenous progenitors of the forebrain (4). Recent reports show that bFGF is capable of larged and thin walled blood vessels as well as newly formed capillaries at the ischemia border zone (IBZ) exerting neuroprotective or vasodilating effects, as well as enhancing the proliferation of the neuronal progeni- (17) . Although the early increase (1 h after stroke) of VEGF could increase the blood-brain barrier (BBB) tors (1, 72) .
To enhance the efficacy of MSCs, gene-modified leakage and hence increase ischemia hemorrhagic transformation, and exacerbate ischemic cell damage, when
MSCs have been used as donor cells for transplantation in stroke models. In these experiments, specific genes, administered 48 h after stroke, VEGF could enhance angiogenesis in the IBZ and significantly improved neuro-such as FGF-2/HGF/BDNF are transfected into the cells before they are transplanted into the brain. These grafted logical recovery (88) . From hMSC administration to the secretion of VEGF by the graft cells, the time course cells subsequently are able to express the target gene in the brain. Kurozumi and coworkers (47,48) transfected highly exceeds 1 h after stroke; hence, VEGF here functions as the angiogenesis promoter and improves the telomerized human MSCs with the BDNF gene using a fiber-mutant F/RGD adenovirus vector and transplanted functional recovery after stroke. HGF has been demonstrated to ameliorate BBB destruction without exacerbat-these cells in stroke rats. BDNF production by MSC-BDNF cells is 23-fold greater than that seen in unmodi-ing cerebral edema, decrease intracranial pressure, and induce angiogenesis. Equally compelling evidence sug-fied MSCs. Stroke rats that received MSC-BDNF display significantly better functional recovery than do gests that grafted MSCs promote neurogenesis. Over the years, laboratory studies have established the subventri-control stroke rats. This research group also conducted a parallel study in which they transfected MSCs with cular zone (SVZ) and subgranular zone (SGZ) as remarkable brain neurogenic sites. The presence of MSCs glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), and neurotrophin 3 in the brain has been shown to promote the induction and migration of new cells from these primary sources (NT3) genes (47) . Stroke rats that received MSC-GDNF, but not those treated with CNTF and NT3, show signifi-Cell Proliferation and Axonal Remodeling. Grafted MSCs could modulate glial cell proliferation and result cantly greater functional improvement than control stroke rats. A study from Ikeda demonstrates that stroke in neuron remyelination as well as synaptogenesis (74) . Oligogenesis and astrocytogenesis are markedly enhanced animals that received bFGF-MSCs show significantly better attenuations of behavioral impairments and infarc-in the SVZ of the ischemia animal models treated with MSCs (55, 73, 74) . In addition to enhancing gliogenesis, tion volumes than those that received nontransfected MSCs (37) . These data suggest that bFGF enhances the reducing apoptosis is shown to be another critical effect of MSCs. Using an anaerobic chamber to duplicate the beneficial effects of MSCs. A relatively new addition to the list of growth factors exerting benefits in stroke is in vivo ischemia scenario in vitro, Gao and colleagues demonstrate that astrocytes, when cocultured with MSCs, HGF. Ischemia animals treated both with and without HGF-modified MSCs exhibit improvement of neurologi-suffer less cell death and apoptosis (28) . In vivo studies indicate that intravenously administration of MCSs in cal deficits, yet those that received HGF-MSCs treatment display superior therapeutic effect to the nonmodi-stroke models could reduce apoptosis in the penumbral zone of the lesion (12,52). fied MSC-treated group (90) .
Even though graft survival rate or neuronal differenti-A recent study demonstrates that MSCs significantly increase astrocytic expression of connexin-43 (Cx43) ation appear to play minor roles in the MSC transplantation therapeutic effect, studies demonstrate that trans-(27), growth associated protein-43 (GAP-43) (55). This Cx43 upregulation is concomitant with altered gap junc-plantation with MSCs that are committed to differentiate into a neuronal phenotype indicate better therapeutic ef-tion intercellular communication (GJIC) with the participation of PI3K signaling pathway (27). In vivo data con-fects. MSCs transfected with Notch intracellular domain and subsequently treated with bFGF, forskolin, and CNTF firm that transplanted MSCs enhance bone morphogenetic protein 2/bone morphogenetic protein 4 (BMP2/4) and have the potential to differentiate into neurons, termed by the authors as bone marrow stromal cell-derived neu-Cx43 expression in astrocytes (86) . Cx43 is the primary component of intercellular channels in astrocytes, while ronal cell (MSDNC) (24) . Transplantation of MSDNCs in stroke models reveals better functional improvement BMP2/4 belongs to a subgroup of the transforming growth factor-β superfamily. BMP2/4 maintains exten-than those treated with MSCs (24) .
Although gene-based strategies appear to improve sive gap junctional communication through Cx43 and hence mediates communication between astrocytes and MSC graft functional effects, the use of viral vectors poses clinical problems, especially with uncontrolled increases synaptogenesis in the IBZ (86) . Compared to nontransplanted ischemic animals, areas of the corpus gene replications that may cause neoplasm, tumors, and even death. An alternative approach to circumvent ad-callosum and the numbers of white matter bundles in the striatum are larger in the IBZ in MSC-treated ischemic verse side effects associated with genetic manipulation, but still facilitating the therapeutic effects of MSCs, is animals (57, 74) ; at the same time, the axons and myelin thickness are increased along with scar thickness being to exogenously deliver neurotrophic factors. Study shows that BDNF delivered along with MSCs signifi-reduced (55, 73) . In contrast, the numbers of microglia and macrophages within the scar wall are reduced (55) . cantly improves the recovery of the stroke animals (11).
In an effort to further improve MSC efficacy, MSC Whether microglia inhibit the axonal regeneration warrants further investigation. transplantation is combined with adjunctive treatment of specific reagents. A cell-permeable inhibitor of caspases, Z-Val-Ala-DL-Asp-fluoromethylketone (Z-VAD), SDF-1/CXCR 4 Chemoattractant Pathway. Stromal cell-derived factor-1 (SDF-1) and its receptor, CXC-is found to enhance graft survival and behavioral recovery (13) when intracerebrally infused together with chemokine receptor-4 (CXCR4), are essential for stem cell migration and seeding. SDF-1 is also termed MSCs into the ischemic region. Nitric oxide has been proven to play an important role in cell proliferation and CXCL12. It is originally found to be expressed by murine and human bone marrow endothelial and endosteal neurogenesis. Intravenous infusion of MSCs with a nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-ammoni-bone lining stromal cells (38) , and later also found in various tissues, including skin (62), epithelial cells in oethyl) aminio] diazen-1-ium-1,2-diolate (DETA/NON Oate) significantly improves functional recovery in human liver bile ducts (45) , and brain endothelium (78) . In the hematopoietic system, SDF-1 is a crucial chem-stroke animals, with accompanying enhancement of vessel perimeter and endothelial cell proliferation. In addi-oattractant for CXCR4-expressing bone marrow-derived cells, including bone marrow stem cells. When SDF-1 tion, such combined DETA/NONOate and MSC grafts lead to increased neurogenesis in the SVZ, as well as is activated, these stem cells migrate out from the bone marrow reservoir to the circulation, replenishing the VEGF and bFGF expression, in the ischemic area compared to single treatments (16).
blood with new cells (22) . In the nonhematopoietic sys-tem, CXCR4-positive cells similarly respond to SDF-1 have isolated pluripotent stem cells with MAPC features from umbilical cord blood (43) , dermis, and skeletal signals secreted by injured organs, and migrate into these areas. Such SDF-1 upregulation and cell migration muscle (85) . D'Ippolito reports that a subpopulation of stem cells are found to subsequently lead to secretion of various trophic factors. In stroke rats, the chemokine SDF-1 which could differentiate into three somatic germ lineages in single cell level is isolated from bone marrow level is significantly increased in the injured hemisphere compared to the spared site (73) . The upregulation of (25) . They refer to these cells as MIAMI cells. MIAMI cells express high levels of CD29, CD63, CD81, SDF-1 is mostly recognized in the IBZ and maintains for up to 30 days after the injury. Of note, CXCR4 is CD122, CD164, HGF receptor (cMet), bone morphogenetic protein receptor 1B (BMPR1B), neurotrophic ty-detected in the transplanted MSCs. The interaction between SDF-1 and CXCR4 serves as the chemoattractant rosine kinase receptor 3 (NTRK3), Oct-4, and Rex-1, and do not express CD34, CD36, CD45, CD117 (cKit), guide for MSC migration towards the impaired site (73) . SDF-1 is also found to be expressed in experimental and HLA-DR. These cells express CD10, which make them distinct from MAPCs. Similar to MAPCs, these neonatal hypoxic-ischemic (HI) injury, with similar spatial pattern to that seen in adult models of ischemic brain cells are telomerase positive and could differentiate in culture without obvious senescent tendency. injury, but the upregulation is only up to 7 days after the injury and not at the later time points (59). SDF-1
Another subpopulation, hBMSCs, with pluripotent differentiation potential was isolated by Yoon (84) . gene expression is regulated by the hypoxia-responsive transcription factor, hypoxia-inducible factor 1(HIF-1) hBMSCs display the capacity for differentiation into cells of all three germ layers and maintain the multipo-(10), and follows a gradient pattern consistent with the hypoxia gradient in the penumbra of stroke animals (34) . tency for more than 140 PDs. These cells express CD90 (Thy1), CD105, and CD117 (c-kit) and lack CD29, In a neonatal HI model, the striatum, but not the hippocampus, displays a gradient of SDF-1 expression follow-CD44, and CD73, which are features that separate them from MSCs. No CD45, CD34, CD133, KDR, Tie2, ing hypoxia. Moreover, specific cell types appear highly sensitive to hypoxia-induced SDF-1 expression. For ex-HLA-1, or HLA-2 is expressed. hBMSCs do not express Oct4; hence, they are also different from MAPCs. The ample, the astrocytes dramatically express SDF-1 in the HI hemisphere, while subsets of neocortical neurons de-mean telomere restriction fragment (TRF) lengths do not show significant differences between 5 and 120 PDs. A crease SDF-1 expression in both the hypoxic and HI affected hemispheres (59). In general, the expression of subsequent study reveals that the underlying mechanism of multipotency consists of both fusion and differentia-SDF-1 following a brain injury serves as significant signal for attracting the bone marrow-derived stem cells to tion (84) . Recently a subset of pluripotent bone-derived stem cells, VSEL stem cells, capable of differentiation migrate into the damaged area, and is crucial for the functional recovery of stroke.
into the three germ layer lineages was reported by Kucia and coworkers (46) . These cells display unique mor-PLURIPOTENT BONE MARROW-DERIVED phology [i.e., small cell body (about 2-4 µm) with rela-STEM CELLS-MAPC, MIAMI, hBMSC, tive large nuclei]. These murine bone marrow-derived AND VSEL stem cells express SSEA-1, Oct-4, Nanog, Rex-1, and Characteristics of MAPC, MIAMI, hBMSC, and VSEL Sca-1, but lack of CD45 (46) . The telomerase activity of this cell type has not been determined yet.
MAPCs were first reported by Verfaillie and colleagues as a population of primitive cells isolated from
Application of MAPC, MIAMI, hBMSC, and VSEL the bone marrow of postnatal human and rodents on Ischemic Injuries (40, 70, 71) . MAPCs do not express CD34, CD45, CD105, CD106, HLA-1, or HLA-DR, but express low Because most of these subpopulations display the capacity of proliferating without obvious senescence or levels of CD44, Thy1, AC133 (human MAPCs), and Sca1 (mouse). MAPCs also express the transcription loss of differentiation potential, they are an ideal cell source for therapy of various diseases. So far, there is factors oct-4, nanog, rex-1, and the cell surface markers SSEA-1 in mouse and SSEA-3, SSEA-4, TRA-1-60, no report on the potential therapeutic effects of transplanting MIAMI cells and VSEL stem cells in ischemia TRA-1-81, and Oct3 in humans. These markers are known to be important for maintaining undifferentiated injury models. hBMSCs, on the other hand, have been applied in myocardial infarction (MI) animal models embryonic stem cells and are downregulated when embryonic stem cells undergo somatic cell commitment (84) . Cardiac function and remodeling are improved in hBMSC-treated animals. A subsequent study demon-and differentiation (9, 33, 35) . MAPCs are capable of differentiation into mesoderm, neuroectoderm, and endo-strates that hBMSCs differentiate into smooth muscle cells, cardiomyocytes, and endothelium cells. Moreover, derm both in vivo and in vitro. Different research groups these cells secrete series of trophic factors such as IGF-relevant to stroke pathology that need to be addressed in order to further optimize stem cell therapy in general. 1, VEGF, bFGF, and HGF. These trophic factors could promote angiogenesis and vasculogenesis. hBMSCs also Neurotrophic cytokine secretion has been proposed as a critical mechanism of the therapeutic effect of bone mar-upregulate the cardiac transcription factors such as GATA-4, Nkx2.5, and MEF2C and hence could pro-row-derived stem cell transplantation. Yet there is no report on the dynamic measurement of the cytokine lev-mote proliferation of endogenous cardiomyocytes. Both endogenous tissue repair and exogenous tissue regenera-els in alert animals. Analysis of cytokine level (i.e., with microdialysis) would help to elucidate the effects of cy-tion have been speculated as underlying mechanisms of the observed beneficial effects of hBMSCs (84) . To tokines. This might shed light on further improving the neuroprotective and neurorestorative benefits of this date, no experiments about hBMSC transplantation in stroke have been reported.
therapy. During brain recovery after stroke, astrocytes act as MAPCs have been examined in both MI and stroke animal models. A study by Penn (unpublished data) pio-a double edged sword. In early stage, astrocytes secrete various neurotrophic factors and benefit the stroke re-neers the allogeneic transplantation of MAPCs (5 injections of 400,000 cells per injection) in an MI rat model covery. In the chronic stage of the injury, the overproliferation of astrocytes induces scar formation, which could induced by ligation of left anterior descending (LAD) coronary artery. Two weeks post-MI, echocardiography then block axon remyelization. Transplanted stroke animals have been shown to exhibit increased astrocyte is performed to evaluate the shortening fraction (calculated as a percentage of end diastolic minus end systolic proliferation rate accompanied by reduction of the scar wall within 4 months after stroke (74) . It is unclear how 2D dimension, divided by end diastolic length). Shortening fraction is used as an indication index. The experi-the astrocytogenesis and the scar formation reach a homeostatic balance. Whether the astrocytogenesis has a ment reveals a significant increase in shortening fraction in MI animals that received MAPCs compared to those time-dependent change (i.e., elevates at early stage and downregulates at later stage) or whether it is the cyto-that received vehicle only. Immunohistological fluorescence analysis is able to visualize GFP-labeled MAPCs kine secreted by the astrocyte itself suppressing the gliogenesis is unknown. Further investigation to determine within the infarcted heart tissue and in the infarct border zones. These data demonstrate that MAPCs can provide these issues will elucidate the influence of astrocytes on stroke recovery process. significant benefit in MI.
A study by Verfaillie and Low reveals that human In stroke or other CNS injuries, microglial cells are activated, known as lesion-reactive microglia (50) . The MAPCs, when transplanted into the ischemia rat brain, could significantly enhance the functional improvement microglial population increases over time in reaction to the injury and peaks a few days later. This process is of the stroke animal (89) . The mechanism of this therapeutic effect might be induced by the trophic factors se-regarded as reactive microgliosis. Lesion-reactive microglia population consists of two subpopulations: the creted by the grafted cells. Although histology examination of the host brain does detect grafted cells expressing resident microglia, which express CD34 and undergo proliferation; and a subpopulation recruited from the markers for astrocytes, oligodendrocytes, and neurons, the morphology of these cells does not recapitulate typi-bone marrow-derived cells (49) . By contrast to reactive microgliosis, Li's study demonstrates that MSC treat-cal cell features. So it is highly unlikely that these cells are robust glial cells or neurons. ment significantly reduces the number of microglia and macrophages 4 months after stroke insult (55) . It is un-To investigate how MAPCs would affect neonatal brain injury, for instance neonatal HI, we performed clear how and when microglia are reduced. Furthermore, activated microglia could remove cellular debris through MAPC transplantation on postnatal day 7 HI rat models (83) . Animals received either syngeneic or allogeneic phagocytosis and perform beneficial function; yet they could also induce nitric oxide and free radicals, which MAPC intrahippocampal injection. No detectable differences in functional improvement between the syngeneic were detrimental (75) . In Alzheimer's disease, it has been suggested that the newly differentiated microglia and allogeneic MAPC-treated groups are detected. Both groups display superior motor function recovery com-derived from bone marrow stem cells, not the resident ones, are responsible for eliminating the amyloid depos-pared to the vehicle group. This study provides evidence that MAPC allogeneic transplantation is a feasible cell-its, thereby playing a beneficial role (76) . However, in Parkinson's disease the majority of bone marrow-derived based therapeutic strategy. microglia express the inducible form of nitric oxide syn-FUTURE DIRECTIONS thase (iNOS) and exert a deleterious role (44) . To date, limited information is available on whether the residual Despite significant advances of bone marrow stem cells in stroke therapy, there are some neglected issues microglia activated by stroke insult would be inhibited mesenchymal stem cell transplantation in stroke patients.
by cytokines from the transplanted cells, whether micro- of these underexplored cellular events will pave the way 
